Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 10,450 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
Loading trial locations…
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
CONTACT
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
CONTACT